EVFM (Evofem Biosciences) Enterprise Value: $52.05 Mil (As of Jun. 27, 2026) ***


What is Evofem Biosciences Enterprise Value?

Evofem Biosciences EVFM -6.07% Enterprise Value is $52.05 Mil as of Jun. 27, 2026. The stock has 5 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Evofem Biosciences's Enterprise Value is $52.05 Mil. Evofem Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.46 Mil. Therefore, Evofem Biosciences's EV-to-EBIT ratio for today is -15.06.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Evofem Biosciences's Enterprise Value is $52.05 Mil. Evofem Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.99 Mil. Therefore, Evofem Biosciences's EV-to-EBITDA ratio for today is -17.43.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Evofem Biosciences's Enterprise Value is $52.05 Mil. Evofem Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $20.24 Mil. Therefore, Evofem Biosciences's EV-to-Revenue ratio for today is 2.57.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Evofem Biosciences's Enterprise Value is $52.05 Mil. Evofem Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.25 Mil. Therefore, Evofem Biosciences's EV-to-OCF ratio for today is -207.38.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Evofem Biosciences's Enterprise Value is $52.05 Mil. Evofem Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.25 Mil. Therefore, Evofem Biosciences's EV-to-FCF ratio for today is -205.74.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Evofem Biosciences  (OTCPK:EVFM) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Evofem Biosciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=52.053/-3.457
=-15.06

Evofem Biosciences's current Enterprise Value is $52.05 Mil.
Evofem Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.46 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Evofem Biosciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=52.053/-2.986
=-17.43

Evofem Biosciences's current Enterprise Value is $52.05 Mil.
Evofem Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.99 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Evofem Biosciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=52.053/20.237
=2.57

Evofem Biosciences's current Enterprise Value is $52.05 Mil.
Evofem Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.24 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Evofem Biosciences's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=52.053/-0.251
=-207.38

Evofem Biosciences's current Enterprise Value is $52.05 Mil.
Evofem Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Evofem Biosciences's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=52.053/-0.253
=-205.74

Evofem Biosciences's current Enterprise Value is $52.05 Mil.
Evofem Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evofem Biosciences Enterprise Value Related Terms


Evofem Biosciences Enterprise Value Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Enterprise Value Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.94 76.24 44.65 47.09 55.75

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.50 48.47 53.65 55.75 52.13

EVFM vs PTIX, ATXI, AGTX: Enterprise Value Comparison

For the Biotechnology subindustry, Evofem Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences Enterprise Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Enterprise Value falls into.



Evofem Biosciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Evofem Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Evofem Biosciences's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of $52.05 Mil mean?
Evofem Biosciences (EVFM) has a Enterprise Value of $52.05 Mil as of Jun. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Evofem Biosciences and its competitors.
Is Evofem Biosciences' Enterprise Value too high?
Evofem Biosciences' current Enterprise Value is $52.05 Mil.
How does Evofem Biosciences' Enterprise Value compare to PTIX and ATXI?
Evofem Biosciences' Enterprise Value of $52.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Enterprise Value is $52.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 18% below its estimated fair value. The current Enterprise Value is $52.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Enterprise Value is $52.05 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.